Intellia Therapeutics, Inc. Forecast, price target & analysts
Intellia Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Intellia Therapeutics, Inc. Classifications & Recommendation:
Intellia Therapeutics, Inc. Price Target
| Target Price | $25.50 |
| Price | $11.71 |
| Potential |
117.76%
register free of charge
|
| Number of Estimates | 26 |
|
26 Analysts have issued a price target Intellia Therapeutics, Inc. 2026 .
The average Intellia Therapeutics, Inc. target price is $25.50.
This is
117.76%
register free of charge
$111.30
850.47%
register free of charge
$7.07
39.62%
register free of charge
|
|
| A rating was issued by 34 analysts: 26 Analysts recommend Intellia Therapeutics, Inc. to buy, 7 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Intellia Therapeutics, Inc. stock has an average upside potential 2026 of
117.76%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 57.88 | 62.69 |
| 59.54% | 8.32% | |
| EBITDA Margin | -905.29% | -728.00% |
| 35.13% | 19.58% | |
| Net Margin | -896.72% | -700.47% |
| 32.39% | 21.89% |
28 Analysts have issued a sales forecast Intellia Therapeutics, Inc. 2025 . The average Intellia Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Intellia Therapeutics, Inc. EBITDA forecast 2025. The average Intellia Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
28 Intellia Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Intellia Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.25 | -4.17 |
| 3.14% | 20.57% | |
| P/E | negative | |
| EV/Sales | 12.19 |
28 Analysts have issued a Intellia Therapeutics, Inc. forecast for earnings per share. The average Intellia Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Intellia Therapeutics, Inc....
Current Intellia Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 16 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 16 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jun 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 29 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
